Geron (NASDAQ:GERN) Releases Earnings Results

Geron (NASDAQ:GERN) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01), Zacks reports. The firm had revenue of $57.48 million for the quarter, compared to analyst estimates of $55.30 million. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.

Here are the key takeaways from Geron’s conference call:

• RYTELO net revenue rose 17% year over year to $57.5 million in the second quarter, while first-half revenue increased approximately 24% year over year.
• RYTELO demand grew 5% sequentially, prescribing accounts increased 8% to approximately 1,575, and the company expects 2026 net product revenue of $220 million-$240 million to land at the mid-to-high end of guidance.
• Management cited encouraging real-world evidence in lower-risk MDS that was generally consistent with the Phase III IMerge trial, supporting RYTELO adoption—particularly in earlier lines of therapy and community treatment centers.
• Geron ended the quarter with $327 million in cash, equivalents, restricted cash, and marketable securities, while maintaining 2026 operating expense guidance of $230 million-$240 million and reporting a 4% first-half decrease in operating expenses.
• The company is evaluating a modification to the interim event threshold for the Phase III IMpactMF myelofibrosis trial after discussions with regulators; although timelines remain unchanged, the base case still calls for final overall-survival analysis in the second half of 2028.

Geron Price Performance

NASDAQ:GERN traded up $0.29 during mid-day trading on Wednesday, hitting $1.63. The company’s stock had a trading volume of 36,057,531 shares, compared to its average volume of 9,380,397. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -14.82 and a beta of 0.61. The company has a current ratio of 6.78, a quick ratio of 4.96 and a debt-to-equity ratio of 0.52. Geron has a fifty-two week low of $1.04 and a fifty-two week high of $2.01. The stock has a fifty day moving average of $1.33 and a 200-day moving average of $1.46.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Institutional Investors Weigh In On Geron

Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its position in shares of Geron by 3,307.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 24,410 shares during the period. Amundi bought a new stake in Geron in the fourth quarter valued at $38,000. Franklin Resources Inc. acquired a new position in Geron during the third quarter worth $45,000. Cibc World Markets Corp acquired a new position in Geron during the fourth quarter worth $48,000. Finally, Atom Investors LP lifted its holdings in shares of Geron by 137.0% during the fourth quarter. Atom Investors LP now owns 37,341 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 21,588 shares during the period. 73.71% of the stock is currently owned by institutional investors.

Key Stories Impacting Geron

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RYTELO revenue beat estimates: Geron reported $57.5 million in second-quarter net product revenue from RYTELO (imetelstat), up 11% from the first quarter and above analysts’ expectations of $55.3 million. The performance suggests continued demand for the company’s recently launched treatment. Geron adds a record 16% as Rytelo drives Q2 revenue beat
• Positive Sentiment: Full-year outlook maintained: Geron reiterated its 2026 RYTELO net product revenue forecast of $220 million to $240 million and projected total operating expenses of $230 million to $240 million, reducing uncertainty around near-term execution. Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Healthy liquidity: The company ended the quarter with $327 million in cash, restricted cash and marketable securities, providing funding for commercialization and ongoing development efforts. Geron also appointed Chinmaya Rath as chief business officer to broaden its leadership team. Geron second-quarter financial results
• Positive Sentiment: Unusually strong call-option activity: Investors purchased 10,326 call options, roughly 1,439% above the average daily volume of 671 contracts. The activity indicates increased speculative bullish interest, though it does not guarantee future gains.
• Negative Sentiment: Quarterly loss missed expectations: Geron reported a loss of $0.02 per share, compared with the consensus estimate of a $0.01 loss. The result matched the year-ago loss and reflects that the company remains unprofitable despite growing product revenue. Geron Q2 Earnings Snapshot

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.